Other antidiabetic medications, mostly used in the G3a and G3b stages rather than in G4, included SGLT2 inhibitors and GLP-1 analogues, highlighting the diversity in antidiabetic treatment choices among CKD patients. Here, SLC5A2 is linked to chronic kidney disease.